Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
| Autor: | Quang Q. Phan, Huy A. Nguyen, Son T. Do, Khoa D. Lam, Tuan Nguyen, Khanh K. Nguyen, Mindie H. Nguyen, Thuan T. Nguyen, Long H. Nguyen, Ruel T. Garcia, Huy N. Trinh |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Genotype Hepatitis C virus Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology California Polyethylene Glycols law.invention Young Adult chemistry.chemical_compound Randomized controlled trial law Pegylated interferon Internal medicine medicine Humans Rapid Virologic Response Aged Hepatology business.industry Ribavirin Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged Viral Load medicine.disease Texas Recombinant Proteins digestive system diseases chemistry Immunology Female Safety business Viral load medicine.drug |
| Zdroj: | Hepatology. 52:1573-1580 |
| ISSN: | 0270-9139 |
| Popis: | Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a multicenter, open-label randomized controlled trial of patients with HCV genotype 6 at five gastroenterology clinics in the western U.S. Patients were stratified by viral load and histologic stage and assigned to receive PEG IFN-α2a 180 μg subcutaneously weekly and weight-based oral RBV 800 to 1,200 mg daily for 24 or 48 weeks. Primary outcome measurement was SVR rate by intention-to-treat analysis. From February 2005 to October 2007 a total of 60 patients (age 51 ± 10 years, 47% male, log HCVRNA 6.3 ± 1.1 IU/mL) were enrolled: 27 patients to 24 weeks and 33 patients to 48 weeks of therapy. In the 24-week and 48-week groups, 96% and 97% achieved early virologic response (P = 0.90); 89% versus 94% achieved end of therapy virologic response (P = 0.48). SVR was achieved in 70% versus 79% of patients assigned to 24 weeks versus 48 weeks (P = 0.45). Rapid virologic response (RVR) was a significant predictor of SVR in the 48-week group and trending towards significance in the 24-week group: 82% and 83% of those with RVR achieved SVR versus 33% and 29% for the 24-week and 48-week groups, respectively (P = 0.07 and P = 0.02). Conclusion: There was no significant difference in SVR rates in patients with HCV genotype 6 treated with PEG IFN-α2a and RBV for 24 versus 48 weeks. (HEPATOLOGY 2010;52:1573-1580) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text